The FDA approved Tris Pharma's Karbinal ER, or carbinoxamine maleate, for pediatric patients 2 years and older, to treat seasonal and perennial allergic rhinitis. The treatment is the first extended-release histamine receptor blocking agent for children's allergies, Tris said.
Tris Pharma's allergy drug for children gets FDA OK
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||